Clinical Trials Logo

Polyradiculoneuropathy clinical trials

View clinical trials related to Polyradiculoneuropathy.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT03275740 Terminated - Healthy Clinical Trials

A First in HumanTrial to Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-06755347

Start date: July 17, 2017
Phase: Phase 1
Study type: Interventional

This phase 1 single ascending dose study will provide a first in human assessment of safety and tolerability of PF-06755347 in healthy adult males as well as adult males and females with Immune Thrombocytopenia (ITP). Pharmacokinetics and pharmacodynamics will also be evaluated.

NCT ID: NCT02317562 Terminated - Clinical trials for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Efficacy and Safety Study of I10E in the Maintenance Treatment of Patients With CIDP: Extension of PRISM Study I10E-1302

PRISM2
Start date: November 2015
Phase: Phase 3
Study type: Interventional

Primary objective: To assess the efficacy of I10E administered at a reduced maintenance dose in sustaining CIDP response after an initial 6-month treatment in PRISM study. (I10E-1302). Secondary objective: To assess the safety of I10E in this patient population.

NCT ID: NCT01225276 Terminated - Clinical trials for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Safety and Efficacy Study of Three Different Dosages of NewGam in Patients With CIDP

POINT
Start date: October 2011
Phase: Phase 2/Phase 3
Study type: Interventional

NewGam (current working title for a new IGIV formulation) is a newly developed human normal immunoglobulin solution ready for intravenous administration (IGIV). This study will evaluate the safety and efficacy of three different dosages of NewGam 10% in patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy.